If anti PD-L1 was not used as first line treatment, this study shows you can still use it as second line.
Patients with poor performance status do better on atezolizumab monotherapy vs. single agent chemotherapy.
Neoadjuvant chemotherapy trial with post op nivolumab for 6 months shows promising results.
For radiation oncologists: omitting radiation in patients with favorable features of 55 years of age and older.
Another KRAS G12C inhibitor. Congrats to FCS Director of Drug Development Manish Patel, MD, one of the authors. Durable responses with less adverse events.
Pembrolizumab plus olaparib did not significantly improve radiographic progression-free survival or overall survival versus new generation hormonal agent and was more toxic.
It seems that PET is better than CT scan in locally advanced disease staging, better in upstaging, and may spare the patient combined modality therapy.
Would you keep treating with CDK4/6 inhibitors and just switch endocrine therapy after failing first line ET+CDK4/6 inhibitor? This trial says YES….
Our radiation oncologists will find this article particularly interesting – more radiation is NOT better.
Targeted therapy in NSCLC, FCS was part of this trial.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
